Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Candida antigen (Primary)
- Indications Warts
- Focus Adverse reactions
- Sponsors Nielsen BioSciences
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016.
- 21 Oct 2015 Planned end date changed from 1 Jun 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.